U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C32H52N4O4
Molecular Weight 556.7797
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 2

SHOW SMILES / InChI
Structure of DEMECARIUM

SMILES

CN(CCCCCCCCCCN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C)C(=O)OC2=CC=CC(=C2)[N+](C)(C)C

InChI

InChIKey=RWZVPVOZTJJMNU-UHFFFAOYSA-N
InChI=1S/C32H52N4O4/c1-33(31(37)39-29-21-17-19-27(25-29)35(3,4)5)23-15-13-11-9-10-12-14-16-24-34(2)32(38)40-30-22-18-20-28(26-30)36(6,7)8/h17-22,25-26H,9-16,23-24H2,1-8H3/q+2

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00944

Demecarium (HUMORSOL®) is an indirect-acting parasympathomimetic agent, also known as a cholinesterase inhibitor and anticholinesterase. Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it down. Application of demecarium (HUMORSOL®) to the eye produces intense miosis and ciliary muscle contraction due to inhibition of cholinesterase, allowing acetylcholine to accumulate at sites of cholinergic transmission. These effects are accompanied by increased capillary permeability of the ciliary body and iris, increased permeability of the blood-aqueous barrier, and vasodilation. Myopia may be induced or, if present, may be augmented by the increased refractive power of the lens that results from the accommodative effect of the drug. Demecarium (HUMORSOL®) indirectly produces some of the muscarinic and nicotinic effects of acetylcholine as quantities of the latter accumulate.

Originator

Curator's Comment: Schmid, O.; US. Patent 2,789,981; April 23, 1957; assigned to Chemie Linz Ag, Austria.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HUMORSOL

Approved Use

Open-angle glaucoma (HUMORSOL® should be used in glaucoma only when shorter-acting miotics have proved inadequate). Conditions obstructing aqueous outflow, such as synechial formation, that are amenable to miotic therapy. Following iridectomy. Accommodative esotropia (accommodative convergent strabismus).

Launch Date

-3.2849281E11
Palliative
HUMORSOL

Approved Use

Open-angle glaucoma (HUMORSOL® should be used in glaucoma only when shorter-acting miotics have proved inadequate). Conditions obstructing aqueous outflow, such as synechial formation, that are amenable to miotic therapy. Following iridectomy. Accommodative esotropia (accommodative convergent strabismus).

Launch Date

-3.2849281E11
PubMed

PubMed

TitleDatePubMed
Effect of topically applied demecarium bromide and echothiophate iodide on intraocular pressure and pupil size in beagles with normotensive eyes and beagles with inherited glaucoma.
1993 Feb
Effect of topically applied 2% pilocarpine and 0.25% demecarium bromide on blood-aqueous barrier permeability in dogs.
1994 Dec
The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs.
2003 Mar
Outcomes of nonsurgical management and efficacy of demecarium bromide treatment for primary lens instability in dogs: 34 cases (1990-2004).
2007 Jul 1
Acute ocular complications from self-administered topical kermes.
2010 Oct
Patents

Sample Use Guides

For glaucoma initial therapy with demecarium (HUMORSOL®) place 1 or 2 drops in the glaucomatous eye. The usual dosage can vary from as much as 1 or 2 drops twice a day to as little as 1 or 2 drops twice a week. For treatment of esotropia with demecarium (HUMORSOL®) 1 drop is given daily for 2 weeks, then 1 drop every 2 days for 2 to 3 weeks. In esotropia uncomplicated by amblyopia or anisometropia, demecarium (HUMORSOL®) may be instilled in both eyes, not more than 1 drop at a time every day for 2 to 3 weeks, as too severe a degree of miosis may interfere with vision. Then reduce the dosage to 1 drop every other day for 3 to 4 weeks and reevaluate the patient's status.
Route of Administration: Topical
Tetramethoquin and demecarium bromide were compared with physostigmine on the hypogastric guinea-pig nerve-vas deferens preparation. Each drug, in bath concentrations of 1 ug/ml, potentiated the response of the vas deferens to nerve stimulation. Subsequent addition of a higher dose of these agents inhibited the response. With demecarium inhibition occurred with 3 to 5 ug/ml.
Name Type Language
DEMECARIUM
VANDF   WHO-DD  
Common Name English
Demecarium [WHO-DD]
Common Name English
DEMECARIUM ION
Common Name English
(M-HYDROXYPHENYL)TRIMETHYLAMMONIUM DECAMETHYLENEBIS(METHYLCARBAMATE)
Systematic Name English
N,N'-BIS(3-TRIMETHYLAMMONIUMPHENOXYCARBONYL(-N,N'-DIMETHYLDECAMETHYLENEDIAMINE
Common Name English
DEMECARIUM CATION
Common Name English
DEMECARIUM [VANDF]
Common Name English
3,3'-(1,10-DECANEDIYLBIS((METHYLIMINO)CARBONYLOXY))BIS(N,N,N-TRIMETHYLBENZENAMINIUM)
Common Name English
BENZENAMINIUM, 3,3'-(1,10-DECANEDIYLBIS((METHYLIMINO)CARBONYLOXY))BIS(N,N,N-TRIMETHYL-
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C47792
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
WHO-VATC QS01EB04
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
WHO-ATC S01EB04
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
Code System Code Type Description
DRUG BANK
DB00944
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
PRIMARY
MESH
C100193
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
PRIMARY
RXCUI
107771
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID2046965
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
PRIMARY
SMS_ID
100000087729
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
PRIMARY
FDA UNII
ILP8XJ8R5K
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
PRIMARY
CAS
16505-84-3
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
PRIMARY
DRUG CENTRAL
801
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
PRIMARY
EVMPD
SUB01577MIG
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
PRIMARY
PUBCHEM
5966
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
PRIMARY
WIKIPEDIA
Demecarium
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
PRIMARY
NCI_THESAURUS
C87481
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
PRIMARY
DAILYMED
ILP8XJ8R5K
Created by admin on Fri Dec 15 16:22:39 UTC 2023 , Edited by admin on Fri Dec 15 16:22:39 UTC 2023
PRIMARY